Skip to content
Screener

AnaptysBio, Inc. ANAB Q1 2026 Annual earnings

Reported May 12, 2026 · Before market open

Revenue$25.6MBeat by $6.7M
EPS-$1.84Miss by $1.52
Revenue estimate$18.9M
EPS estimate-$0.32

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$14.0M
EPS estimate$0.11

Financials

Q1 2026

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$1.72B+201%
Enterprise value$1.47B+171%
P/S7.4×+2.8×

Profitability

See full
Operating margin17.6%+9.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Debt / equity0×-0.5×
Current ratio7.6×-0.7×

FAQ

When did AnaptysBio, Inc. report Q1 2026 earnings?
AnaptysBio, Inc. (ANAB) reported Q1 2026 earnings on May 12, 2026 before market open.
What were AnaptysBio, Inc.'s Q1 2026 revenue and EPS?
AnaptysBio, Inc. reported revenue of $25.6M and eps of $-1.84 for Q1 2026.
Did AnaptysBio, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $18.9M by $6.7M. EPS missed the consensus estimate of $-0.32 by $1.52.
How did AnaptysBio, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 8.0% from $27.8M a year earlier and eps declined 43.8% from $-1.28.
Where can I find AnaptysBio, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-216745) and the 10-K/A periodic report (0001193125-26-187044) directly on SEC EDGAR. The filing index links above go to sec.gov.